Earnings Feed
Start Free
Kiniksa Pharmaceuticals International, plc·4

Apr 3, 4:40 PM ET

Ragosa Mark 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Apr 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Kiniksa (KNSA) CFO Mark Ragosa Exercises Options and Receives Awards

What Happened
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals (KNSA), had multiple derivative and equity award transactions on April 1, 2026. He (i) converted/exercised 5,187 derivative units into Class A ordinary shares, (ii) received awards totaling 54,550 restricted/performance share units (31,150 + 7,800 + 15,600), and (iii) had 2,510 shares withheld/sold to cover tax liabilities for proceeds of $120,806 (sale price reported at $48.13 per share). Several small derivative conversions (1,750; 1,591; 1,846) appear in the filing as conversions/dispositions tied to the overall exercise/settlement activity.

Key Details

  • Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (appears timely; Form 4 due within two business days).
  • Tax withholding sale: 2,510 shares disposed at $48.13 for $120,806 (code F = tax withholding).
  • Derivative activity: conversion/exercise entries totaling 5,187 shares (code M). Several conversion/disposition line items (1,750; 1,591; 1,846) are listed at $0 (typical for vest/settlement entries).
  • Awards received: three grant entries totaling 54,550 RSUs/PSUs (code A) recorded at $0 (derivative awards).
  • Shares owned after the transactions: not specified in the provided filing details.
  • Footnotes of note:
    • RSUs generally convert 1-for-1 into Class A shares (F1); various RSU grants vest over four years with vesting commencement dates of April 1 in 2023, 2024, 2025, and 2026 (F2, F3, F6–F8).
    • PSUs convert into shares based on performance, up to 200% per unit and vest no later than Jan 30, 2029 (F4–F5).
  • Transaction codes: M = exercise/conversion of derivative; A = award/grant; F = tax withholding/sale to satisfy tax obligation.

Context

  • This was largely award vesting/conversion activity (not an open-market investment). The 2,510-share disposition was a withholding/sale to pay taxes rather than a voluntary open-market sale (common with RSU/option settlements).
  • PSUs are performance-based and may convert into a variable number of shares depending on achievement of pre-set goals; RSU awards typically convert 1-for-1.
  • These filings are factual disclosures of compensation-related equity activity and do not by themselves indicate Ragosa’s broader market views.

Insider Transaction Report

Form 4
Period: 2026-04-01
Kiniksa Pharmaceuticals International, plcKNSA
Ragosa Mark
CHIEF FINANCIAL OFFICER
Transactions
  • Exercise/Conversion

    Class A Ordinary Share

    [F1]
    2026-04-01+5,187→ 17,273 total
  • Tax Payment

    Class A Ordinary Share

    2026-04-01$48.13/sh−2,510$120,806→ 14,763 total
  • Award

    Share Option

    [F2]
    2026-04-01+31,150→ 31,150 total
    Exercise: $48.13Exp: 2036-03-31→ Class A Ordinary Share (31,150 underlying)
  • Award

    Restricted Share Unit

    [F1][F3]
    2026-04-01+7,800→ 7,800 total
    → Class A Ordinary Share (7,800 underlying)
  • Award

    Performance Share Unit

    [F4][F5]
    2026-04-01+15,600→ 15,600 total
    → Class A Ordinary Share (15,600 underlying)
  • Exercise/Conversion

    Restricted Share Unit

    [F1][F6]
    2026-04-01−1,750→ 1,750 total
    → Class A Ordinary Share (1,750 underlying)
  • Exercise/Conversion

    Restricted Share Unit

    [F1][F7]
    2026-04-01−1,591→ 3,182 total
    → Class A Ordinary Share (1,591 underlying)
  • Exercise/Conversion

    Restricted Share Unit

    [F1][F8]
    2026-04-01−1,846→ 5,536 total
    → Class A Ordinary Share (1,846 underlying)
Footnotes (8)
  • [F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
  • [F2]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2026.
  • [F3]The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter.
  • [F4]Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee
  • [F5]Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply.
  • [F6]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023.
  • [F7]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024.
  • [F8]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025.
Signature
/s/ Douglas Barry, Attorney-in-Fact|2026-04-03

Documents

1 file
  • 4
    form4-04032026_080402.xmlPrimary